#United States #West Chester #Plexitome #Ophthalmics #Corneal Treatment

Introduction to Plexitome™

Plexitome™, a groundbreaking medical device, has officially launched as a result of a strategic partnership between Plexitome Medical and VEO Ophthalmics, known for their innovations in ophthalmic technology. Designed for anterior stromal puncture (ASP), this device aims to revolutionize how medical professionals treat recurrent corneal erosions (RCE) and other epithelial basement membrane dystrophies (EBMD).

Features of Plexitome™

The device distinguishes itself from traditional methods by utilizing a disc array measuring 6.2 mm in diameter, which contains approximately 675 meticulously crafted micro-spikes. This unique design enables the Plexitome™ to offer both precision and consistency when performing corneal surgery. The micro-spikes are engineered to deliver controlled punctures through Bowman's layer of the cornea without causing visible scarring, which is a limitation often seen with conventional tools.

The innovation doesn’t stop there: through five separate imprints, this device can create up to 3,375 individual epithelial attachment points. This capability significantly aids in promoting corneal healing while minimizing the chances of recurrence of the conditions it treats. This is a remarkable advancement in clinical practices aimed at enhancing patient outcomes and satisfaction.

Expert Opinions

Dr. Edward Chaum, the Founder and Chief Medical Officer at Plexitome Medical, expressed enthusiasm regarding the new device's potential: "Plexitome™ represents a significant step forward in the management of corneal disorders, particularly in the optical axis. It improves outcomes by removing the unpredictability associated with manual ASP methods." This sentiment is echoed by Ron Gilliland, CEO of VEO Ophthalmics, who stated, "Plexitome™ is sure to reinvent how cornea specialists utilize anterior stromal puncture. We look forward to collaborating with Plexitome Medical to distribute this cutting-edge technology to its intended users."

Practical Applications and Benefits

Clinical usage of Plexitome™ has shown promising results. It can effectively penetrate Bowman's layer regardless of whether the epithelium is debrided or remains intact. The device has also been shown to foster stable epithelial attachments in challenging treatments, where traditional ASP methods often fall short. Moreover, it may reduce healing times for large corneal abrasions, offering additional advantages in patients with erosive conditions.

One of the most exciting aspects of this partnership and product launch is the global commercial rollout led by VEO Ophthalmics. Their commitment to providing comprehensive access, training, and support for corneal specialists and surgical teams is paramount to ensuring that the new technology achieves its full potential in clinical settings across the U.S and beyond.

Conclusion

As innovations like Plexitome™ come to the forefront of ophthalmic technology, patient care is expected to improve significantly. The unique attributes of this device not only set a new standard for anterior stromal puncture but also foster positive outcomes for individuals suffering from recurrent corneal conditions. For more information or to request a demonstration of Plexitome™, please visit the company website.

About Plexitome™

Plexitome™ is a patented micro-spike array device uniquely developed for safe and precise anterior stromal puncture, addressing issues related to recurrent corneal erosion and EBMD without the scarring typical of traditional methods.

About VEO Ophthalmics

VEO Ophthalmics, LLC, has established itself as a leader in surgical technologies within the ophthalmic field. They focus on enhancing patient care by collaborating with leading ophthalmic surgeons to drive innovation and improve product offerings.